SciELO - Scientific Electronic Library Online

 
vol.32 número3Midostaurin en combinación de quimioterápia como tratamiento de leucémia mieloblástica aguda con mutación FTL3, a propósito de un casoTratamiento de la eritrodisestesia palmoplantar con una fórmula magistral de urea 20% + triamcinolona acetónido 0,2% + lidocaína 2% índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Revista de la OFIL

versión On-line ISSN 1699-714Xversión impresa ISSN 1131-9429

Resumen

SAEZ-TORRES-DE VICENTE, M; FERRIS-VILLANUEVA, M; REDONDO-GALAN, C  y  RANGEL-MAYORAL, JF. Skin reaction due to remdesivir in a patient with SARS-CoV-2 disease. Rev. OFIL·ILAPHAR [online]. 2022, vol.32, n.3, pp.299-300.  Epub 25-Sep-2023. ISSN 1699-714X.  https://dx.doi.org/10.4321/s1699-714x20220003000015.

In December 2019, a new infectious disease with the official name of COVID-19 was detected for the first time in the Chinese city of Wuhan, caused by a new type of coronavirus called SARS-CoV-2 virus, the infection has spread rapidly and widely throughout the world, which is why on March 11, 2020, the World Health Organization declared it a pandemic. As it is a new infection, there is currently no evidence to recommend a specific treatment, currently the only drug with an indication authorized by the European Medicines Agency (EMA) is remdesivir.

We present the case of an adverse reaction to remdesivir, although it was not serious, it is worth highlighting the importance of reporting adverse effects and more in novel drugs like this one.

Palabras clave : COVID-19; adverse effect; remdesivir.

        · resumen en Español     · texto en Español     · Español ( pdf )